Summit Therapeutics Inc SMMT

AstraZeneca just locked in a price to own 12% of Summit Therapeutics that the open market refuses to match, and two clinical deadlines in 2026 will determine whether Wall Street or the pharma giant read ivonescimab correctly.

Summit Therapeutics stock jumped Tuesday after AstraZeneca made a $2 billion investment in the smaller biotech.

AstraZeneca stock sinks as management announces $2 billion investment in Summit Therapeutics. But should you buy the dip in AZN shares today? Let’s find out!

AstraZeneca's (AZN) $2 billion investment in Summit Therapeutics (SMMT) is a "win-win" and potential

A preferred-equity investment secures collaboration access without the cost and integration risk of an acquisition.

The companies will start by testing ivonescimab with an AstraZeneca ADC in gastrointestinal cancers

The deal would give AstraZeneca exposure to a promising cancer treatment without acquiring the company outright.

The equity investment comes alongside a deal to test Summit’s ivonescimab alongside potentially many AstraZeneca drugs — but doesn’t hand the pharmaceutical company any ownership rights.

AstraZeneca PLC (LSE:AZN, NASDAQ:AZN), the FTSE 100 pharmaceutical company, has won positive responses from UBS and Jefferies after investing $2 billion in Summit Therapeutics and agreeing a cancer drug collaboration. UBS said the investment gives AstraZeneca exposure to the programmed...

Investing.com - U.S. stock index futures hovered around the flatline on Tuesday after soaring bond yields dented Wall Street in the prior session, as investors looked ahead to a fresh batch of economic data.

Summit Therapeutics (SMMT) shares rose early Tuesday after British drugmaker AstraZeneca (AZN) agree

Summit Therapeutics (NASDAQ:SMMT) shares rose 22% in pre-market trading on Tuesday after AstraZeneca (NASDAQ:AZN) agreed to make a $2 billion strategic equity investment in the biotechnology company. The investment will be made through newly issued convertible preferred shares at an effective common stock equivalent price of $18.

The firms will collaborate on Summit’s experimental new medicine as well as researching how it could be combined with Astra’s treatments.

Investing.com -- British stocks gave up earlier gains on Tuesday to close lower despite slower UK shop price inflation offset lingering U.S.-Iran uncertainty, while heavyweight AstraZeneca gained after taking a $2 billion stake in Summit Therapeutics.

AstraZeneca PLC (LSE:AZN, NASDAQ:AZN), the FTSE 100 pharmaceutical company, will invest $2 billion in Summit Therapeutics Inc as part of a wider cancer drug collaboration. The investment will give AstraZeneca rights equivalent to about 12% of Summit’s outstanding common stock, or about 10.6%...